One-Liner
A retail-trader app filtering only AI-discovered drug pipeline readouts with probabilistic Phase III forecasts, at $19.99/month.
AI Thinking Process
Verb Transplant engine: 'Phase III readout calendar' verb-shape transplanted from biotech investing to AI-discovered-drug-only sub-market. Retail trader targeting.
Consumer-facing readout calendar + probabilistic Phase III forecast for the ~200 AI-discovered drug compounds in late-stage trials. $19.99/month targeting r/biotechplays community.
BiopharmaCatalyst ($19.99/mo) covers all pharma readouts but no AI-drug filter. Citeline ($30K institutional). BioMed Nexus AI Drug Tracker ($5K institutional). No retail-grade AI-drug-only product found.
BiopharmaCatalyst could add AI-drug filter toggle as a feature in 8 weeks. Product survives only if probabilistic Phase III forecast model adds genuine ML value BiopharmaCatalyst can't quickly replicate.
Survived at 35% (borderline, relaxed threshold). Biggest worry: pure-filter version is feature-absorbable in one quarter. Product survival requires defensible probabilistic model.
r/biotechplays runs volunteer-curated AI-drug-tracker spreadsheets that compress willingness-to-pay. BiopharmaCatalyst dev cadence allows 2-week build for AI-drug filter toggle.
FEATURE gate failed: BiopharmaCatalyst at $19.99/mo owns the buyer relationship. AI-drug filter is a 2-week build for them. Probabilistic forecasting is publicly replicable. No durable differentiation surface.
Killed in Pass 2 deepening. Feature-absorbable by BiopharmaCatalyst within 8–12 weeks. Verb-transplant engine produced an interesting direction but economic moat doesn't survive incumbent-feature analysis.
Kill Reason
BiopharmaCatalyst at $19.99/month already owns the retail-biotech-trader buyer relationship and can ship an AI-discovered drug filter toggle within 8–12 weeks. The probabilistic forecasting model is publicly replicable using clinical-trial datasets. No durable differentiation surface justifies a competing subscription at the same price point.
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: BiopharmaCatalyst at $19.99/month already owns the retail-biotech-trader buyer relationship and can ship an AI-discovered drug filter toggle within 8–12 weeks. The probabilistic forecasting model is publicly replicable using clinical-trial datasets. No durable differentiation surface justifies a competing subscription at the same price point.
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.